Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Deborah Wexler MD, MSc
Deborah J. Wexler MD, MSc Associate Editor
Kathleen Dungan MD, MPH
Kathleen M. Dungan MD, MPH Advisory Board
Richard Pratley MD
Richard E. Pratley MD Associate Editor
See All Experts
Published in Diabetes

Journal Scan / Research · August 22, 2021

Extended-Release Naltrexone/Bupropion in Patients With T2D Already on Incretin Agents

International Journal of Obesity (2005)

 

 Save  Recommend
 Share

Additional Info

International Journal of Obesity (2005)
Extended-Release Naltrexone/Bupropion Is Safe and Effective Among Subjects With Type 2 Diabetes Already Taking Incretin Agents: A Post-Hoc Analysis of the LIGHT Trial
Int J Obes (Lond) 2021 Aug 01;45(8)1687-1695, S Wharton, P Yin, M Burrows, E Gould, J Blavignac, RAG Christensen, E Kamran, F Camacho, M Barakat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated